Key result
Sitagliptin significantly enhanced renovascular responses to AngII in isolated perfused kidneys from both Lean-ZSF1 and Obese-ZSF1 rats (P=0.0367), persisting in metabolic syndrome.
Why the study?
Does sitagliptin augment angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome?
Does sitagliptin augment angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome?
p-value: p=0.0367
Sitagliptin enhances renovascular responses to angiotensin II in rats with SHR genes, persisting even in the presence of diabetic nephropathy and metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Raises caution for sitagliptin in metabolic syndrome regarding renal AngII responses; hypothesis-generating and requires human confirmation.
Tofovic et al. (2010) studied Metabolic syndrome and hypertension (n=21). Sitagliptin vs. Untreated was evaluated on Renovascular responses (changes in perfusion pressure) to AngII (0.1 nmol/L) (p=0.0367). Sitagliptin significantly enhanced renovascular responses to AngII in isolated perfused kidneys from both Lean-ZSF1 and Obese-ZSF1 rats (P=0.0367), persisting in metabolic syndrome.